Philadelphia, Pennsylvania, October 18, 2013 – Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today announced that the U.S. Food and Drug Administration (FDA) has approved ZORVOLEX™ (diclofenac) capsules, a nonsteroidal anti-inflammatory drug (NSAID),  for the treatment of mild to moderate acute pain in adults[1]. 

Click Here to read more